EcoDrugPlus

Rac-Beta Serine/threonine-Protein Kinase

Ensembl ID : ENSOKIG00005042198
Gene Symbol: LOC109872584
2 Cross references
190 Possible Orthologues:

Raf-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSOKIG00005005365
Gene Symbol: RAF1
3 Cross references
201 Possible Orthologues:

Raf-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSOKIG00005015922
Gene Symbol: RAF1
3 Cross references
201 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 1

Ensembl ID : ENSOKIG00005048807
Gene Symbol: ROCK1
1 Cross references
206 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 2

Ensembl ID : ENSOKIG00005016710
Gene Symbol: ROCK2
3 Cross references
218 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 2

Ensembl ID : ENSOKIG00005005634
Gene Symbol: ROCK2
3 Cross references
219 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 2

Ensembl ID : ENSOKIG00005023725
Gene Symbol: ROCK2
1 Cross references
219 Possible Orthologues:

Sem1 26s Proteasome Subunit

Ensembl ID : ENSOKIG00005036474
Gene Symbol: SEM1
1 Cross references
150 Possible Orthologues:

Src Proto-Oncogene, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSOKIG00005003877
Gene Symbol: SRC
3 Cross references
186 Possible Orthologues:

Src Proto-Oncogene, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSOKIG00005001075
Gene Symbol: SRC
3 Cross references
186 Possible Orthologues:

Tek Receptor Tyrosine Kinase

Ensembl ID : ENSOKIG00005001210
Gene Symbol: TEK
3 Cross references
159 Possible Orthologues:

Tgf-Beta Receptor Type-1

Ensembl ID : ENSOKIG00005033993
Gene Symbol: LOC109875264
3 Cross references
150 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).